The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Health Technology Assessment

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3310/HTA8110PMID 14982655
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Cost-Utility Analysis of Subcutaneous Methotrexate in the Treatment of Patients with Rheumatoid Arthritis in the UK

  2025cites this paper
• Discrete Event Simulation in R using the ‘Simmer’ Package for Health Economic Modelling: A Tutorial and Illustration in Colon Cancer

  2025cites this paper
• Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran

  2024cites this paper
• Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis

  2024cites this paper
• Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments

  2024cites this paper
• Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China.

  2024cites this paper
• Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach

  2023cites this paper
• Distance‐Based Topological Descriptors on Ternary Hypertree Networks

  2022cites this paper
• Pharmacometrics: The Already-Present Future of Precision Pharmacology

  2022cites this paper
• Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States

  2021cites this paper
• Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs.

  2021cites this paper
• Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer.

  2021influential citation
• Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China

  2020cites this paper
• Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions

  2020cites this paper
• Cost–utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis

  2020cites this paper
• Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience

  2020cites this paper
• Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs

  2020cites this paper
• FAILED INITIAL TUMOR NECROSIS INHIBITOR (TNFI) THERAPY – WHAT NEXT FOR RHEUMATOID ARTHRITIS PATIENTS?

  2019cites this paper
• Costs, effectiveness and cost-effectiveness of biological drugs in the treatment of rheumatoid arthritis and inflammatory bowel diseases

  2019cites this paper
• This is a repository copy of Extrapolating survival from randomised trials using external data : a review of methods

  2019cites this paper
• Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer

  2018influential citation
• Expert’s Approach of Neoplasms in the Most Ubiquitous Autoimmune Rheumatic Disease

  2018cites this paper
• Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients.

  2018cites this paper
• Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.

  2018cites this paper
• Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States

  2018cites this paper
• Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece

  2017cites this paper
• Adding Events to a Markov Model Using DICE Simulation

  2017cites this paper
• Modeling Clinical Outcomes in Prostate Cancer: Application and Validation of the Discrete Event Simulation Approach.

  2017cites this paper
• Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models

  2017cites this paper
• The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.

  2016cites this paper
• Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.

  2016cites this paper
• Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea.

  2016cites this paper
• Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods

  2016cites this paper
• Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review

  2016cites this paper
• The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review

  2015influential citation
• Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.

  2015cites this paper
• Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece

  2015cites this paper
• The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.

  2015cites this paper
• Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.

  2015cites this paper
• Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.

  2015cites this paper
• Clopidogrel Versus Aspirin in Patients with Recent Ischemic Stroke and Established Peripheral Artery Disease: An Economic Evaluation in a Chinese Setting

  2015cites this paper
• Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis

  2015cites this paper
• Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars.

  2015cites this paper
• Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

  2014cites this paper
• Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis

  2014cites this paper
• Practices Task Force Modeling Using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research

  2014cites this paper
• Health Economic Modelling of Treatment Sequences for Rheumatoid Arthritis: A Systematic Review

  2014influential citation
• How to Select the Right Cost-Effectiveness Model?

  2014cites this paper
• Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal

  2014cites this paper
• Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results.

  2014cites this paper
• Cost–Effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting

  2014cites this paper
• Comparative Effectiveness of Tacrolimus-Based Steroid Sparing versus Steroid Withdrawal Regimens in Patients with Kidney Transplantation: Results from Discrete Event Simulation Modeling

  2014cites this paper
• Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models

  2014cites this paper
• Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of rheumatoid arthritis

  2014cites this paper
• Decision Making in Health and Medicine: Estimation, calibration, and validation

  2014cites this paper
• Decision making in health and medicine: Integrating evidence and values, second edition

  2014cites this paper
• Modeling rheumatoid arthritis using different techniques - a review of model construction and results

  2014influential citation
• Effectiveness of eHealth Interventions and Information Needs in Palliative Care: A Systematic Literature Review

  2014cites this paper
• Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.

  2013cites this paper
• Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review

  2013cites this paper
• Biologisten lääkkeiden kustannusvaikuttavuus nivelreuman hoidossa: järjestelmällinen kirjallisuuskatsaus

  2013influential citation
• Les utilités EQ-5D et SF-6D dans la polyarthrite débutante

  2012cites this paper
• Modeling the risks and benefits of depression treatment for children and young adults.

  2012cites this paper
• Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy

  2012cites this paper
• Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis

  2012cites this paper
• Modeling the effectiveness of initial management strategies for ductal carcinoma in situ.

  2012cites this paper
• Cost-Effectiveness of the Third-Agent Class in Treatment-Naive Human Immunodeficiency Virus-Infected Patients in Portugal

  2012cites this paper
• Bayesian methods for evidence synthesis in cost-effectiveness analysis

  2012cites this paper
• Cost Effectiveness of Different Treatment Strategies in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis in China

  2012cites this paper
• The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.

  2012cites this paper
• Economic Evaluations in Rheumatoid Arthritis

  2012cites this paper
• An economic evaluation of adaptive e-learning devices to promote weight loss via dietary change for people with obesity

  2012cites this paper
• Systematic review of head cooling in adults after traumatic brain injury and stroke.

  2012cites this paper
• Tocilizumab for the treatment of systemic juvenile idiopathic arthritis

  2012cites this paper
• Modeling Using Discrete Event Simulation

  2012cites this paper
• Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis

  2012influential citation
• Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.

  2011cites this paper
• A clinician's critique of rheumatoid arthritis health economic models.

  2011cites this paper
• Adaptive e-learning to improve dietary behaviour: a systematic review and cost-effectiveness analysis.

  2011cites this paper
• Cost‐effectiveness of biologic response modifiers compared to disease‐modifying antirheumatic drugs for rheumatoid arthritis: A systematic review

  2011influential citation
• Evaluating Treatment Strategies in Patients with Early Rheumatoid Arthritis: Merging Modeling Theory with Clinical Practice

  2011cites this paper
• Development of the Birmingham Rheumatoid Arthritis Model: past, present and future plans.

  2011cites this paper
• Principles of health economics and application to rheumatic disorders

  2011cites this paper
• A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis

  2011cites this paper
• National Institute for Health and Clinical Excellence

  2010cites this paper
• Access to innovative treatments for rheumatoid arthritis in New Zealand . A comparison with Australia and the UK . MAY 2 0 1 0

  2010cites this paper
• Treatment strategies in early Rheumatoid Arthritis.

  2010influential citation
• Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs

  2010cites this paper
• Cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting

  2010cites this paper
• Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

  2010cites this paper
• A review of discrete event simulation in National Coordinating Centre for Health Technology Assessment-funded work and a case study exploring the cost-effectiveness of testing for thrombophilia in patients presenting with an initial idiopathic venous thromboembolism

  2010cites this paper
• Evidence Review Group Report Tocilizumab for the treatment of rheumatoid arthritis

  2009cites this paper
• Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.

  2009cites this paper
• Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity

  2009cites this paper
• NICE guidelines on anti-tumor necrosis factor therapy for RA

  2009cites this paper
• Rapid testing for group B streptococcus during labour: a test accuracy study with evaluation of acceptability and cost-effectiveness.

  2009cites this paper
• Psychological interventions for postnatal depression: cluster randomised trial and economic evaluation. The PoNDER trial.

  2009cites this paper
• Are adverse effects incorporated in economic models? An initial review of current practice.

  2009cites this paper
• Cost-effectiveness of Early Use of Etanercept in the Treatment of Rheumatoid Arthritis

  2009cites this paper
• COST-EFFECTIVENESS EVALUATION OF TOCILIZUMAB IN ROMANIAN HEALTH CARE SYSTEM

  2009cites this paper